Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, CLIA, Western Blot), Specimen (Blood, Saliva, Urine), Application (Infectious Diseases, Endocrinology), End User (Hospitals & Clinics, Laboratories) - Global Forecast to 2030

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY RESEARCH
    • 2.1.1.1 Key secondary sources
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY RESEARCH
    • 2.1.2.1 Key primary sources
    • 2.1.2.2 Key objectives of primary research
    • 2.1.2.3 Key data from primary sources
    • 2.1.2.4 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
  • 2.2.2 COMPANY PRESENTATIONS & PRIMARY INTERVIEWS
  • 2.2.3 TOP-DOWN APPROACH
• 2.3 DATA TRIANGULATION
• 2.4 MARKET SHARE ANALYSIS
• 2.5 STUDY ASSUMPTIONS
  • 2.5.1 MARKET ASSUMPTIONS
  • 2.5.2 GROWTH RATE ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
  • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.6.2 SCOPE-RELATED LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 IMMUNOASSAY MARKET OVERVIEW
• 4.2 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT AND COUNTRY
• 4.3 IMMUNOASSAY MARKET: GEOGRAPHICAL SNAPSHOT
• 4.4 IMMUNOASSAY MARKET: REGIONAL MIX

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing incidence of chronic and infectious diseases
      • 5.2.1.1.1 Increased use of immunoassays in oncology
      • 5.2.1.1.2 Rising use of immunoassays in diagnostic applications
      • 5.2.1.1.3 High geriatric population
    • 5.2.1.2 Increased demand for blood donations in healthcare systems and surgical procedures
    • 5.2.1.3 Growth in biotechnology & biopharmaceutical industries
    • 5.2.1.4 Increasing adoption of immunoassay-based POC and rapid testing
    • 5.2.1.5 Supportive government regulatory policies and initiatives
    • 5.2.1.6 Increased consumption of drugs, alcohol, and cannabis
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Stringent requirements for approval of immunoassay instruments and consumables
    • 5.2.2.2 Technical hurdles of immunoassay kits
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increasing growth opportunities in emerging economies
    • 5.2.3.2 Focus on importance of companion diagnostics
    • 5.2.3.3 Development of condition-specific biomarkers and tests
    • 5.2.3.4 Integration of microfluidics in immunoassays
    • 5.2.3.5 Improving immunoassay diagnostic technologies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Design challenges and low quality of antibodies
    • 5.2.4.2 Dearth of skilled professionals
• 5.3 REGULATORY ANALYSIS
  • 5.3.1 REGULATORY FRAMEWORK
    • 5.3.1.1 North America
      • 5.3.1.1.1 US
      • 5.3.1.1.2 Canada
    • 5.3.1.2 Europe
      • 5.3.1.2.1 Russia
    • 5.3.1.3 Asia Pacific
      • 5.3.1.3.1 Japan
      • 5.3.1.3.2 China
      • 5.3.1.3.3 India
      • 5.3.1.3.4 Indonesia
      • 5.3.1.3.5 South Korea
    • 5.3.1.4 Middle East
      • 5.3.1.4.1 Saudi Arabia
    • 5.3.1.5 Latin America
      • 5.3.1.5.1 Mexico
      • 5.3.1.5.2 Brazil
    • 5.3.1.6 Africa
  • 5.3.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 ELISA
  • 5.4.2 ADJACENT TECHNOLOGIES
    • 5.4.2.1 Microfluidics and miniaturized platforms
  • 5.4.3 COMPLEMENTARY TECHNOLOGIES
    • 5.4.3.1 Lateral flow assays
• 5.5 TRADE ANALYSIS
  • 5.5.1 IMPORT DATA FOR HS CODE 382200, 2019-2024
  • 5.5.2 EXPORT DATA FOR HS CODE 382200, 2019-2024
• 5.6 PATENT ANALYSIS
• 5.7 VALUE CHAIN ANALYSIS
• 5.8 SUPPLY CHAIN ANALYSIS
• 5.9 ECOSYSTEM ANALYSIS
  • 5.9.1 ROLE IN ECOSYSTEM
• 5.10 PORTER'S FIVE FORCES ANALYSIS
  • 5.10.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.10.2 BARGAINING POWER OF SUPPLIERS
  • 5.10.3 BARGAINING POWER OF BUYERS
  • 5.10.4 THREAT OF SUBSTITUTES
  • 5.10.5 THREAT OF NEW ENTRANTS
• 5.11 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.11.2 KEY BUYING CRITERIA
• 5.12 KEY CONFERENCES & EVENTS, 2025-2026
• 5.13 PRICING ANALYSIS
  • 5.13.1 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY KEY PLAYER, 2022-2024
  • 5.13.2 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY ANAYZERS, BY REGION, 2022-2024
  • 5.13.3 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY TYPE, 2022-2024
• 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.15 CASE STUDY ANALYSIS
  • 5.15.1 PORTABLE MICROFLUIDIC CHEMILUMINESCENT IMMUNOASSAY TO BE USED FOR RAPID COVID 19 IMMUNITY MONITORING
  • 5.15.2 MICROFLUIDIC-BASED IMMUNOASSAY TO HELP IN EARLY CANCER DETECTION
  • 5.15.3 LUMINEX-BASED MULTIPLEX IMMUNOASSAY TO AID AUTOIMMUNE DISEASE PROFILING
• 5.16 INVESTMENT & FUNDING SCENARIO
• 5.17 IMPACT OF AI/GEN AI ON IMMUNOASSAY MARKET
  • 5.17.1 MARKET POTENTIAL FOR IMMUNOASSAY PRODUCTS
  • 5.17.2 FUTURE OF AI/GEN AI IN IMMUNOASSAY MARKET
• 5.18 IMPACT OF 2025 US TARIFF ON IMMUNOASSAY MARKET
  • 5.18.1 INTRODUCTION
  • 5.18.2 KEY TARIFF RATES
  • 5.18.3 PRICE IMPACT ANALYSIS
  • 5.18.4 IMPACT ON COUNTRY/REGION
    • 5.18.4.1 North America
      • 5.18.4.1.1 US
    • 5.18.4.2 Europe
      • 5.18.4.2.1 Germany
      • 5.18.4.2.2 UK and France
    • 5.18.4.3 Asia Pacific
      • 5.18.4.3.1 China
      • 5.18.4.3.2 Japan
      • 5.18.4.3.3 India
  • 5.18.5 IMPACT ON END-USE INDUSTRIES
    • 5.18.5.1 Hospitals & clinics
    • 5.18.5.2 Clinical laboratories
    • 5.18.5.3 Blood banks
    • 5.18.5.4 Home care settings

6 IMMUNOASSAY MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 REAGENTS & KITS
  • 6.2.1 ELISA REAGENTS & KITS
    • 6.2.1.1 Increased use of high-throughput screening in drug discovery programs to drive segment
  • 6.2.2 RAPID TEST REAGENTS & KITS
    • 6.2.2.1 High demand for preliminary screening tests in remote areas to propel segment growth
  • 6.2.3 ELISPOT REAGENTS & KITS
    • 6.2.3.1 High sensitivity, functionality, and adaptability of ELISpot technology to aid segment growth
  • 6.2.4 CLIA REAGENTS & KITS
    • 6.2.4.1 Better diagnosis and higher specificity to augment segment growth
  • 6.2.5 IFA REAGENTS & KITS
    • 6.2.5.1 Better adaptability in clinical diagnostics to support segment growth
  • 6.2.6 WESTERN BLOT REAGENTS & KITS
    • 6.2.6.1 Western blot reagents & kits to be considered gold standard for infectious disease test result validation
  • 6.2.7 OTHER REAGENTS & KITS
• 6.3 ANALYZERS
  • 6.3.1 IMMUNOASSAY ANALYZERS MARKET, BY TYPE
    • 6.3.1.1 Open-ended systems
      • 6.3.1.1.1 Better flexibility and wider availability to drive segment growth
    • 6.3.1.2 Closed-ended systems
      • 6.3.1.2.1 Higher precision and better automation to fuel segment growth
  • 6.3.2 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE
    • 6.3.2.1 Rental purchase
      • 6.3.2.1.1 Increased convenience and reduced liability to boost segment growth
    • 6.3.2.2 Outright purchase
      • 6.3.2.2.1 Inflated cost of immunoassay testing technologies to limit market growth

7 IMMUNOASSAY MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 ELISA
  • 7.2.1 BETTER SENSITIVITY AND QUICKER RESULTS TO DRIVE MARKET
• 7.3 CLIA
  • 7.3.1 GOOD SPECIFICITY, WIDE LINEAR RANGE, AND HIGH SENSITIVITY TO AID MARKET GROWTH
• 7.4 IFA
  • 7.4.1 IFA TO DIAGNOSE ANTIBODIES AND ANALYZE SMALL BIOLOGICAL AND NON-BIOLOGICAL MOLECULES
• 7.5 RAPID TESTS
  • 7.5.1 FASTER RESULTS AND EASE OF USE TO DRIVE ADOPTION IN POINT-OF-CARE DIAGNOSIS AND EMERGENCY CARE SETTINGS
• 7.6 WESTERN BLOTTING
  • 7.6.1 ABILITY TO DETECT AND CONFIRM ANTIBODIES OF RETROVIRUSES TO SPUR MARKET GROWTH
• 7.7 ELISPOT
  • 7.7.1 HIGH SENSITIVITY, SPECIFICITY, AND VERSATILITY TO PROPEL MARKET GROWTH
• 7.8 OTHER TECHNOLOGIES

8 IMMUNOASSAY MARKET, BY SPECIMEN

• 8.1 INTRODUCTION
• 8.2 BLOOD
  • 8.2.1 HIGH RELIABILITY AND INCREASED NEED DURING SURGICAL PROCEDURES TO AID MARKET GROWTH
• 8.3 SALIVA
  • 8.3.1 ADVANCEMENTS IN IMMUNOASSAY-BASED SALIVA TESTS TO AUGMENT MARKET GROWTH
• 8.4 URINE
  • 8.4.1 INCREASING USE BY LAW ENFORCEMENT AGENCIES AND RISING PREVALENCE OF KIDNEY DISEASES TO FAVOR MARKET GROWTH
• 8.5 OTHER SPECIMENS

9 IMMUNOASSAY MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 INFECTIOUS DISEASES
  • 9.2.1 RISING PREVALENCE OF CHRONIC INFECTIOUS DISEASES TO DRIVE MARKET
• 9.3 ENDOCRINOLOGY
  • 9.3.1 RISING INCIDENCE OF DIABETES TO AUGMENT MARKET GROWTH
• 9.4 CARDIOLOGY
  • 9.4.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES TO SUPPORT MARKET GROWTH
• 9.5 AUTOIMMUNE DISORDERS
  • 9.5.1 HIGH INCIDENCE AND PREVALENCE OF AUTOIMMUNE DISEASES TO AUGMENT MARKET GROWTH
• 9.6 ALLERGY DIAGNOSTICS
  • 9.6.1 GROWING PREVALENCE OF ALLERGIES TO AID MARKET GROWTH
• 9.7 ONCOLOGY
  • 9.7.1 RISING BURDEN OF CANCER AND GROWING EMPHASIS ON EARLY DETECTION TO PROPEL MARKET GROWTH
• 9.8 BONE & MINERAL DISORDERS
  • 9.8.1 INCREASING PREVALENCE OF OSTEOPOROSIS, VITAMIN D DEFICIENCY, AND ARTHRITIS TO AID MARKET GROWTH
• 9.9 DRUG MONITORING & TESTING
  • 9.9.1 RISING DRUG ABUSE AND INCREASING ILLICIT DRUG CONSUMPTION TO ACCELERATE MARKET GROWTH
• 9.10 BLOOD SCREENING
  • 9.10.1 RISING EMPHASIS ON BLOOD DONATIONS TO FAVOR MARKET GROWTH
• 9.11 NEWBORN SCREENING
  • 9.11.1 TECHNOLOGICAL ADVANCEMENTS AND FAVORABLE GOVERNMENT INITIATIVES TO PROPEL MARKET GROWTH
• 9.12 OTHER APPLICATIONS

10 IMMUNOASSAY MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOSPITALS & CLINICS
  • 10.2.1 GROWING PATIENT POPULATION AND RISING TESTING VOLUME TO DRIVE MARKET
• 10.3 CLINICAL LABORATORIES
  • 10.3.1 INCREASING NUMBER OF ACCREDITED LABORATORIES TO DRIVE MARKET
• 10.4 HOME CARE SETTINGS
  • 10.4.1 RISING UTILIZATION OF POC DIAGNOSTICS AND AT-HOME ANTIGEN DIAGNOSIS TO PROPEL MARKET GROWTH
• 10.5 BLOOD BANKS
  • 10.5.1 INCREASING NUMBER OF ACCIDENTS AND RISING DEMAND FOR BLOOD DURING SURGERIES TO SPUR MARKET GROWTH

11 IMMUNOASSAY MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 US to dominate North American immunoassay market during forecast period
  • 11.2.3 CANADA
    • 11.2.3.1 Increasing government support and rising incidence of chronic diseases to augment market growth
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 High healthcare spending and favorable government initiatives to propel market growth
  • 11.3.3 ITALY
    • 11.3.3.1 Rising geriatric population and increasing cancer prevalence to spur market growth
  • 11.3.4 FRANCE
    • 11.3.4.1 Increased use of POC testing and favorable reimbursement policies to boost market growth
  • 11.3.5 SPAIN
    • 11.3.5.1 Increasing adoption of technologically advanced immunoassay systems to augment market growth
  • 11.3.6 UK
    • 11.3.6.1 Government support for disease diagnostics and favorable investment scenario to drive market
  • 11.3.7 RUSSIA
    • 11.3.7.1 Increasing access to quality healthcare and developing pharmaceutical industry to favor market growth
  • 11.3.8 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 JAPAN
    • 11.4.2.1 Increasing investments in healthcare technologies and research activities to fuel market growth
  • 11.4.3 CHINA
    • 11.4.3.1 Increasing government investments and rising geriatric population to accelerate maket growth
  • 11.4.4 INDIA
    • 11.4.4.1 Growing medical tourism and improving healthcare infrastructure to propel market growth
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Increasing incidence of cancer and rising focus on blood donations to favor market growth
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Rising healthcare spending and increasing research investments to fuel market growth
  • 11.4.7 INDONESIA
    • 11.4.7.1 High geriatric population and favorable government healthcare policies to accelerate market growth
  • 11.4.8 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 High incidence of infectious diseases and presence of academic & research institutes to boost market growth
  • 11.5.3 MEXICO
    • 11.5.3.1 Increasing geriatric population and rising popularity of medical tourism to propel market growth
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 LACK OF SKILLED LABORATORY PERSONNEL AND UNFAVORABLE REIMBURSEMENT POLICIES TO LIMIT MARKET GROWTH

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN IMMUNOASSAY MARKET
• 12.3 REVENUE ANALYSIS, 2020-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Region footprint
    • 12.5.5.3 Product footprint
    • 12.5.5.4 Specimen footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 12.6.5.1 List of key startups/SMEs
    • 12.6.5.2 Competitive benchmarking of key startups/SMEs
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
  • 12.7.1 FINANCIAL METRICS
  • 12.7.2 COMPANY VALUATION
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES/APPROVALS/ ENHANCEMENTS
  • 12.9.2 DEALS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 ABBOTT
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product approvals
      • 13.1.1.3.2 Deals
      • 13.1.1.3.3 Expansions
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Right to win
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 F. HOFFMANN-LA ROCHE LTD.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product launches and approvals
      • 13.1.2.3.2 Deals
      • 13.1.2.3.3 Expansions
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Right to win
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 SIEMENS HEALTHINEERS AG
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product launches and approvals
      • 13.1.3.3.2 Deals
      • 13.1.3.3.3 Expansions
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Right to win
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 DANAHER
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Product launches and approvals
      • 13.1.4.3.2 Deals
      • 13.1.4.3.3 Expansions
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Right to win
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses & competitive threats
  • 13.1.5 THERMO FISHER SCIENTIFIC INC.
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Product approvals
      • 13.1.5.3.2 Deals
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Right to win
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses & competitive threats
  • 13.1.6 REVVITY
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product approvals
      • 13.1.6.3.2 Other developments
  • 13.1.7 BECTON, DICKINSON AND COMPANY (BD)
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Expansions
  • 13.1.8 DIASORIN S.P.A.
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product launches and approvals
      • 13.1.8.3.2 Deals
  • 13.1.9 BIO-RAD LABORATORIES, INC.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product launches
      • 13.1.9.3.2 Deals
  • 13.1.10 QUIDELORTHO CORPORATION
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Product approvals
      • 13.1.10.3.2 Deals
      • 13.1.10.3.3 Expansions
  • 13.1.11 BIOMERIEUX
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Product launches and approvals
      • 13.1.11.3.2 Deals
  • 13.1.12 QIAGEN
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Deals
  • 13.1.13 SYSMEX CORPORATION
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Deals
      • 13.1.13.3.2 Expansions
  • 13.1.14 AGILENT TECHNOLOGIES, INC.
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
    • 13.1.14.3 Recent developments
      • 13.1.14.3.1 Product launches and approvals
      • 13.1.14.3.2 Deals
      • 13.1.14.3.3 Other developments
  • 13.1.15 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products offered
• 13.2 OTHER PLAYERS
  • 13.2.1 MERCK KGAA
  • 13.2.2 MERIDIAN BIOSCIENCE
  • 13.2.3 BIO-TECHNE
  • 13.2.4 CELLABS
  • 13.2.5 ABNOVA CORPORATION
  • 13.2.6 J. MITRA & CO. PVT. LTD.
  • 13.2.7 TOSOH CORPORATION (TOSOH BIOSCIENCES)
  • 13.2.8 CELL SCIENCES
  • 13.2.9 ENZO BIOCHEM INC.
  • 13.2.10 CREATIVE DIAGNOSTICS
  • 13.2.11 BOSTER BIOLOGICAL TECHNOLOGY
  • 13.2.12 ELABSCIENCE BIONOVATON INC.
  • 13.2.13 WAK-CHEMIE MEDICAL GMBH
  • 13.2.14 SERA CARE
  • 13.2.15 EPITOPE DIAGNOSTICS, INC.
  • 13.2.16 KAMIYA BIOMEDICAL COMPANY
  • 13.2.17 GYROS PROTEIN TECHNOLOGIES AB
  • 13.2.18 TRIVITRON HEALTHCARE
  • 13.2.19 INBIOS INTERNATIONAL, INC.
  • 13.2.20 MACCURA BIOTECHNOLOGY CO., LTD.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS

List of Tables

• TABLE 1 IMMUNOASSAY MARKET: INCLUSIONS & EXCLUSIONS
• TABLE 2 IMMUNOASSAY MARKET: KEY DATA FROM PRIMARY SOURCES
• TABLE 3 IMMUNOASSAY MARKET: MARKET ASSUMPTIONS
• TABLE 4 IMMUNOASSAY MARKET: RISK ANALYSIS
• TABLE 5 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
• TABLE 6 PROJECTED NUMBER OF CANCER PATIENTS, BY CANCER TYPE, 2015 VS. 2018 VS. 2035 (UNITS)
• TABLE 7 DETECTION TIME OF DRUG OR DRUG CLASS IN URINE TESTING
• TABLE 8 ESTIMATED PERCENTAGE INCREASE IN GERIATRIC POPULATION, BY REGION, 2022 VS. 2030 VS. 2050
• TABLE 9 RECENT DEVELOPMENTS IN IMMUNOASSAY MARKET, 2021-2023
• TABLE 10 NEW TESTS LAUNCHED BY KEY PLAYERS, 2021-2023
• TABLE 11 LAB-ON-CHIP IMMUNOASSAYS/DEVICES/SYSTEMS OFFERED BY KEY PLAYERS
• TABLE 12 US: CLASSIFICATION AND RISK LEVEL OF IMMUNOASSAY PRODUCTS
• TABLE 13 EUROPE: CLASSIFICATION AND RISK LEVEL OF IN-VIRTO DIAGNOSTIC DEVICES
• TABLE 14 RUSSIA: CLASSIFICATION AND RISK LEVEL OF IN-VIRTO DIAGNOSTIC DEVICES
• TABLE 15 JAPAN: CLASSIFICATION OF IN-VIRTO DIAGNOSTIC REAGENTS
• TABLE 16 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
• TABLE 17 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
• TABLE 18 INDONESIA: REGISTRATION PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES
• TABLE 19 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
• TABLE 20 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
• TABLE 21 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
• TABLE 22 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 23 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 24 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 25 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 26 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 27 CONVENTIONAL IMMUNOASSAY METHODS AND TECHNIQUES
• TABLE 28 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN IMMUNOASSAY MARKET
• TABLE 29 IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019-2024 (USD MILLION)
• TABLE 30 EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019-2024 (USD MILLION)
• TABLE 31 IMMUNOASSAY MARKET: ROLE IN ECOSYSTEM
• TABLE 32 IMMUNOASSAY MARKET: PORTER'S FIVE FORCES
• TABLE 33 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
• TABLE 34 KEY BUYING CRITERIA, BY END USER
• TABLE 35 IMMUNOASSAY MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025-DECEMBER 2026
• TABLE 36 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY KEY PLAYER, 2022-2024 (USD)
• TABLE 37 AVERAGE SELLING PRICE TREND OF CLINICAL IMMUNOASSAY ANALYZERS, BY REGION, 2022-2024 (USD)
• TABLE 38 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY TYPE, 2022-2024 (USD)
• TABLE 39 CASE STUDY 1: PORTABLE MICROFLUIDIC CHEMILUMINESCENT IMMUNOASSAY TO BE USED FOR RAPID COVID 19 IMMUNITY MONITORING
• TABLE 40 CASE STUDY 2: MICROFLUIDIC-BASED IMMUNOASSAY TO HELP IN EARLY CANCER DETECTION
• TABLE 41 CASE STUDY 3: LUMINEX-BASED MULTIPLEX IMMUNOASSAY TO AID AUTOIMMUNE DISEASE PROFILING
• TABLE 42 US ADJUSTED RECIPROCAL TARIFF RATES
• TABLE 43 IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 44 KEY REAGENTS & KITS AVAILABLE IN MARKET
• TABLE 45 IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 46 IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 47 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 48 EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 49 ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 50 LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 51 ELISA REAGENTS & KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 52 NORTH AMERICA: ELISA REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 53 EUROPE: ELISA REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 54 ASIA PACIFIC: ELISA REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 55 LATIN AMERICA: ELISA REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 56 RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 57 NORTH AMERICA: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 58 EUROPE: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 59 ASIA PACIFIC: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 60 LATIN AMERICA: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 61 ELISPOT REAGENTS & KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 62 NORTH AMERICA: ELISPOT REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 63 EUROPE: ELISPOT REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 64 ASIA PACIFIC: ELISPOT REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 65 LATIN AMERICA: ELISPOT REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 66 CLIA REAGENTS & KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 67 NORTH AMERICA: CLIA REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 68 EUROPE: CLIA REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 69 ASIA PACIFIC: CLIA REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 70 LATIN AMERICA: CLIA REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 71 IFA REAGENTS & KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 72 NORTH AMERICA: IFA REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 73 EUROPE: IFA REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 74 ASIA PACIFIC: IFA REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 75 LATIN AMERICA: IFA REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 76 WESTERN BLOT REAGENTS & KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 77 NORTH AMERICA: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 78 EUROPE: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 79 ASIA PACIFIC: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 80 LATIN AMERICA: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 81 OTHER REAGENTS & KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 82 NORTH AMERICA: OTHER REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 83 EUROPE: OTHER REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 84 ASIA PACIFIC: OTHER REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 85 LATIN AMERICA: OTHER REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 86 KEY ANALYZERS AVAILABLE IN MARKET
• TABLE 87 IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 88 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 89 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 90 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 91 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 92 IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 93 OPEN-ENDED SYSTEMS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 94 NORTH AMERICA: OPEN-ENDED SYSTEMS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 95 EUROPE: OPEN-ENDED SYSTEMS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 96 ASIA PACIFIC: OPEN-ENDED SYSTEMS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 97 LATIN AMERICA: OPEN-ENDED SYSTEMS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 98 CLOSED-ENDED SYSTEMS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 99 NORTH AMERICA: CLOSED-ENDED SYSTEMS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 100 EUROPE: CLOSED-ENDED SYSTEMS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 101 ASIA PACIFIC: CLOSED-ENDED SYSTEMS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 102 LATIN AMERICA: CLOSED-ENDED SYSTEMS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 103 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 104 RENTAL PURCHASE MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 105 NORTH AMERICA: RENTAL PURCHASE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 106 EUROPE: RENTAL PURCHASE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 107 ASIA PACIFIC: RENTAL PURCHASE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 108 LATIN AMERICA: RENTAL PURCHASE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 109 OUTRIGHT PURCHASE MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 110 NORTH AMERICA: OUTRIGHT PURCHASE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 111 EUROPE: OUTRIGHT PURCHASE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 112 ASIA PACIFIC: OUTRIGHT PURCHASE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 113 LATIN AMERICA: OUTRIGHT PURCHASE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 114 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 115 IMMUNOASSAY TECHNOLOGY MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 116 NORTH AMERICA: IMMUNOASSAY TECHNOLOGY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 117 EUROPE: IMMUNOASSAY TECHNOLOGY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 118 ASIA PACIFIC: IMMUNOASSAY TECHNOLOGY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 119 LATIN AMERICA: IMMUNOASSAY TECHNOLOGY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 120 KEY ELISA TECHNOLOGIES AVAILABLE IN MARKET
• TABLE 121 IMMUNOASSAY MARKET FOR ELISA, BY REGION, 2023-2030 (USD MILLION)
• TABLE 122 NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 123 EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 124 ASIA PACIFIC: IMMUNOASSAY MARKET ELISA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 125 LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 126 IMMUNOASSAY MARKET FOR CLIA, BY REGION, 2023-2030 (USD MILLION)
• TABLE 127 NORTH AMERICA: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 128 EUROPE: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 129 ASIA PACIFIC: IMMUNOASSAY MARKET CLIA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 130 LATIN AMERICA: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 131 IMMUNOASSAY MARKET FOR IFA, BY REGION, 2023-2030 (USD MILLION)
• TABLE 132 NORTH AMERICA: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 133 EUROPE: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 134 ASIA PACIFIC: IMMUNOASSAY MARKET IFA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 135 LATIN AMERICA: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 136 KEY RAPID TESTS AVAILABLE IN MARKET
• TABLE 137 IMMUNOASSAY MARKET FOR RAPID TESTS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 138 NORTH AMERICA: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 139 EUROPE: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 140 ASIA PACIFIC: IMMUNOASSAY MARKET RAPID TESTS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 141 LATIN AMERICA: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 142 KEY WESTERN BLOTTING SYSTEMS AVAILABLE IN MARKET
• TABLE 143 IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY REGION, 2023-2030 (USD MILLION)
• TABLE 144 NORTH AMERICA: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 145 EUROPE: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 146 ASIA PACIFIC: IMMUNOASSAY MARKET WESTERN BLOTTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 147 LATIN AMERICA: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 148 IMMUNOASSAY MARKET FOR ELISPOT, BY REGION, 2023-2030 (USD MILLION)
• TABLE 149 NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISPOT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 150 EUROPE: IMMUNOASSAY MARKET FOR ELISPOT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 151 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISPOT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 152 LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISPOT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 153 IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 154 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 155 EUROPE: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 156 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 157 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 158 IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 159 IMMUNOASSAY SPECIMEN MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 160 NORTH AMERICA: IMMUNOASSAY SPECIMEN MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 161 EUROPE: IMMUNOASSAY SPECIMEN MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 162 ASIA PACIFIC: IMMUNOASSAY SPECIMEN MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 163 LATIN AMERICA: IMMUNOASSAY SPECIMEN MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 164 IMMUNOASSAY MARKET FOR BLOOD, BY REGION, 2023-2030 (USD MILLION)
• TABLE 165 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 166 EUROPE: IMMUNOASSAY MARKET FOR BLOOD, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 167 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 168 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 169 IMMUNOASSAY MARKET FOR SALIVA, BY REGION, 2023-2030 (USD MILLION)
• TABLE 170 NORTH AMERICA: IMMUNOASSAY MARKET FOR SALIVA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 171 EUROPE: IMMUNOASSAY MARKET FOR SALIVA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 172 ASIA PACIFIC: IMMUNOASSAY MARKET FOR SALIVA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 173 LATIN AMERICA: IMMUNOASSAY MARKET FOR SALIVA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 174 IMMUNOASSAY MARKET FOR URINE, BY REGION, 2023-2030 (USD MILLION)
• TABLE 175 NORTH AMERICA: IMMUNOASSAY MARKET FOR URINE, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 176 EUROPE: IMMUNOASSAY MARKET FOR URINE, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 177 ASIA PACIFIC: IMMUNOASSAY MARKET FOR URINE, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 178 LATIN AMERICA: IMMUNOASSAY MARKET FOR URINE, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 179 IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 180 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 181 EUROPE: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 182 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 183 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 184 IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 185 IMMUNOASSAY APPLICATION MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 186 NORTH AMERICA: IMMUNOASSAY APPLICATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 187 EUROPE: IMMUNOASSAY APPLICATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 188 ASIA PACIFIC: IMMUNOASSAY APPLICATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 189 LATIN AMERICA: IMMUNOASSAY APPLICATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 190 IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 191 NORTH AMERICA: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 192 EUROPE: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 193 ASIA PACIFIC: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 194 LATIN AMERICA: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 195 IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY REGION, 2023-2030 (USD MILLION)
• TABLE 196 NORTH AMERICA: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 197 EUROPE: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 198 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 199 LATIN AMERICA: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 200 KEY PRODUCTS AVAILABLE FOR CARDIOLOGY APPLICATIONS
• TABLE 201 IMMUNOASSAY MARKET FOR CARDIOLOGY, BY REGION, 2023-2030 (USD MILLION)
• TABLE 202 NORTH AMERICA: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 203 EUROPE: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 204 ASIA PACIFIC: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 205 LATIN AMERICA: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 206 IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 207 NORTH AMERICA: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 208 EUROPE: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 209 ASIA PACIFIC: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 210 LATIN AMERICA: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 211 IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 212 NORTH AMERICA: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 213 EUROPE: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 214 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 215 LATIN AMERICA: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 216 INCREASING INCIDENCE OF CANCER, BY REGION, 2021 VS. 2030 VS. 2040 (MILLION)
• TABLE 217 IMMUNOASSAY MARKET FOR ONCOLOGY, BY REGION, 2023-2030 (USD MILLION)
• TABLE 218 NORTH AMERICA: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 219 EUROPE: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 220 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 221 LATIN AMERICA: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 222 KEY PRODUCTS AVAILABLE FOR BONE & MINERAL DISORDERS
• TABLE 223 IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 224 NORTH AMERICA: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 225 EUROPE: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 226 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 227 LATIN AMERICA: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 228 KEY PRODUCTS AVAILABLE FOR DRUG MONITORING & TESTING
• TABLE 229 KEY IMMUNOASSAY PRODUCTS AVAILABLE FOR DRUG MONITORING & TESTING
• TABLE 230 IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY REGION, 2023-2030 (USD MILLION)
• TABLE 231 NORTH AMERICA: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 232 EUROPE: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 233 ASIA PACIFIC: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 234 LATIN AMERICA: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 235 IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY REGION, 2023-2030 (USD MILLION)
• TABLE 236 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 237 EUROPE: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 238 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 239 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 240 KEY PRODUCTS AVAILABLE FOR NEWBORN SCREENING
• TABLE 241 IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY REGION, 2023-2030 (USD MILLION)
• TABLE 242 NORTH AMERICA: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 243 EUROPE: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 244 ASIA PACIFIC: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 245 LATIN AMERICA: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 246 IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 247 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 248 EUROPE: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 249 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 250 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 251 IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 252 IMMUNOASSAY END USER MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 253 NORTH AMERICA: IMMUNOASSAY END USER MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 254 EUROPE: IMMUNOASSAY END USER MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 255 ASIA PACIFIC: IMMUNOASSAY END USER MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 256 LATIN AMERICA: IMMUNOASSAY END USER MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 257 IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 258 NORTH AMERICA: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 259 EUROPE: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 260 ASIA PACIFIC: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 261 LATIN AMERICA: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 262 IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 263 NORTH AMERICA: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 264 EUROPE: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 265 ASIA PACIFIC: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 266 LATIN AMERICA: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 267 IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 268 NORTH AMERICA: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 269 EUROPE: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 270 ASIA PACIFIC: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 271 LATIN AMERICA: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 272 IMMUNOASSAY MARKET FOR BLOOD BANKS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 273 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 274 EUROPE: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 275 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 276 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 277 IMMUNOASSAY MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 278 NORTH AMERICA: KEY MACROINDICATORS
• TABLE 279 NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 280 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 281 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 282 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 283 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 284 NORTH AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 285 NORTH AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 286 NORTH AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 287 NORTH AMERICA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 288 US: NUMBER OF IN VITRO DIAGNOSTICS TESTS CONDUCTED, 2022-2030 (BILLION UNITS)
• TABLE 289 US: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 290 US: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 291 US: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 292 US: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 293 US: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 294 US: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 295 US: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 296 US: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 297 CANADA: ESTIMATED PREVALENCE OF DIABETES, 2024 VS. 2034
• TABLE 298 CANADA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 299 CANADA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 300 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 301 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 302 CANADA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 303 CANADA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 304 CANADA: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 305 CANADA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 306 EUROPE: KEY MACROINDICATORS
• TABLE 307 EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 308 EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 309 EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 310 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 311 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 312 EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 313 EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 314 EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 315 EUROPE: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 316 GERMANY: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 317 GERMANY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 318 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 319 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 320 GERMANY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 321 GERMANY: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 322 GERMANY: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 323 GERMANY: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 324 ITALY: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 325 ITALY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 326 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 327 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 328 ITALY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 329 ITALY: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 330 ITALY: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 331 ITALY: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 332 FRANCE: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 333 FRANCE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 334 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 335 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 336 FRANCE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 337 FRANCE: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 338 FRANCE: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 339 FRANCE: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 340 SPAIN: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 341 SPAIN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 342 SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 343 SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 344 SPAIN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 345 SPAIN: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 346 SPAIN: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 347 SPAIN: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 348 UK: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 349 UK: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 350 UK: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 351 UK: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 352 UK: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 353 UK: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 354 UK: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 355 UK: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 356 RUSSIA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 357 RUSSIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 358 RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 359 RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 360 RUSSIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 361 RUSSIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 362 RUSSIA: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 363 RUSSIA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 364 REST OF EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 365 REST OF EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 366 REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 367 REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 368 REST OF EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 369 REST OF EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 370 REST OF EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 371 REST OF EUROPE: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 372 ASIA PACIFIC: KEY MACROINDICATORS
• TABLE 373 ASIA PACIFIC: IMMUNOASSAY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 374 ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 375 ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 376 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 377 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 378 ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 379 ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 380 ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 381 ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 382 JAPAN: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 383 JAPAN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 384 JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 385 JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 386 JAPAN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 387 JAPAN: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 388 JAPAN: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 389 JAPAN: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 390 CHINA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 391 CHINA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 392 CHINA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 393 CHINA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 394 CHINA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 395 CHINA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 396 CHINA: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 397 CHINA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 398 INDIA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 399 INDIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 400 INDIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 401 INDIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 402 INDIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 403 INDIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 404 INDIA: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 405 INDIA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 406 AUSTRALIA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 407 AUSTRALIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 408 AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 409 AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 410 AUSTRALIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 411 AUSTRALIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 412 AUSTRALIA: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 413 AUSTRALIA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 414 SOUTH KOREA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 415 SOUTH KOREA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 416 SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 417 SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 418 SOUTH KOREA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 419 SOUTH KOREA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 420 SOUTH KOREA: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 421 SOUTH KOREA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 422 INDONESIA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 423 INDONESIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 424 INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 425 INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 426 INDONESIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 427 INDONESIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 428 INDONESIA: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 429 INDONESIA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 430 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 431 REST OF ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 432 REST OF ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 433 REST OF ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 434 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 435 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 436 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 437 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 438 LATIN AMERICA: KEY MACROINDICATORS
• TABLE 439 LATIN AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 440 LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 441 LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 442 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 443 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 444 LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 445 LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 446 LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 447 LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 448 BRAZIL: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 449 BRAZIL: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 450 BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 451 BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 452 BRAZIL: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 453 BRAZIL: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 454 BRAZIL: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 455 BRAZIL: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 456 MEXICO: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 457 MEXICO: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 458 MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 459 MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 460 MEXICO: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 461 MEXICO: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 462 MEXICO: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 463 MEXICO: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 464 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 465 REST OF LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 466 REST OF LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 467 REST OF LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 468 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 469 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 470 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 471 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 472 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 473 MIDDLE EAST & AFRICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 474 MIDDLE EAST & AFRICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 475 MIDDLE EAST & AFRICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 476 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 477 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 478 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 479 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 480 OVERVIEW OF KEY STRATEGIES DEPLOYED BY MAJOR PLAYERS IN IMMUNOASSAY MARKET
• TABLE 481 IMMUNOASSAY MARKET: DEGREE OF COMPETITION
• TABLE 482 IMMUNOASSAY MARKET: REGION FOOTPRINT
• TABLE 483 IMMUNOASSAY MARKET: PRODUCT FOOTPRINT
• TABLE 484 IMMUNOASSAY MARKET: SPECIMEN FOOTPRINT
• TABLE 485 IMMUNOASSAY MARKET: LIST OF KEY STARTUPS/SME PLAYERS
• TABLE 486 IMMUNOASSAY MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/ SME PLAYERS, BY REGION
• TABLE 487 IMMUNOASSAY MARKET: PRODUCT LAUNCHES/APPROVALS/ENHANCEMENTS, JANUARY 2022-JULY 2025
• TABLE 488 IMMUNOASSAY MARKET: DEALS, JANUARY 2022-JULY 2025
• TABLE 489 ABBOTT: COMPANY OVERVIEW
• TABLE 490 ABBOTT: PRODUCTS OFFERED
• TABLE 491 ABBOTT: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 492 ABBOTT: DEALS, JANUARY 2022-JUNE 2025
• TABLE 493 ABBOTT: EXPANSIONS, JANUARY 2022-JUNE 2025
• TABLE 494 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
• TABLE 495 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
• TABLE 496 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 497 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022-JUNE 2025
• TABLE 498 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2022-JUNE 2025
• TABLE 499 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
• TABLE 500 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
• TABLE 501 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 502 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022-JUNE 2025
• TABLE 503 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2022-JUNE 2025
• TABLE 504 DANAHER: COMPANY OVERVIEW
• TABLE 505 DANAHER: PRODUCTS OFFERED
• TABLE 506 DANAHER: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 507 DANAHER: DEALS, JANUARY 2022-JUNE 2025
• TABLE 508 DANAHER: EXPANSIONS, JANUARY 2022-JUNE 2025
• TABLE 509 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
• TABLE 510 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
• TABLE 511 THERMO FISHER SCIENTIFIC INC.: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 512 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022-JUNE 2025
• TABLE 513 REVVITY: COMPANY OVERVIEW
• TABLE 514 REVVITY: PRODUCTS OFFERED
• TABLE 515 REVVITY: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 516 REVVITY: OTHER DEVELOPMENTS, JANUARY 2022-JUNE 2025
• TABLE 517 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW
• TABLE 518 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED
• TABLE 519 BECTON, DICKINSON AND COMPANY (BD): EXPANSIONS, JANUARY 2022-JUNE 2025
• TABLE 520 DIASORIN S.P.A.: COMPANY OVERVIEW
• TABLE 521 DIASORIN S.P.A.: PRODUCTS OFFERED
• TABLE 522 DIASORIN S.P.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 523 DIASORIN S.P.A.: DEALS, JANUARY 2022-JUNE 2025
• TABLE 524 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
• TABLE 525 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
• TABLE 526 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2022-JUNE 2025
• TABLE 527 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022-JUNE 2025
• TABLE 528 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
• TABLE 529 QUIDELORTHO CORPORATION: PRODUCTS OFFERED
• TABLE 530 QUIDELORTHO CORPORATION: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 531 QUIDELORTHO CORPORATION: DEALS, JANUARY 2022-JUNE 2025
• TABLE 532 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2022-JUNE 2025
• TABLE 533 BIOMERIEUX: COMPANY OVERVIEW
• TABLE 534 BIOMERIEUX: PRODUCTS OFFERED
• TABLE 535 BIOMERIEUX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 536 BIOMERIEUX: DEALS, JANUARY 2022-JUNE 2025
• TABLE 537 QIAGEN: COMPANY OVERVIEW
• TABLE 538 QIAGEN: PRODUCTS OFFERED
• TABLE 539 QIAGEN: DEALS, JANUARY 2022-JUNE 2025
• TABLE 540 SYSMEX CORPORATION: COMPANY OVERVIEW
• TABLE 541 SYSMEX CORPORATION: PRODUCTS OFFERED
• TABLE 542 SYSMEX CORPORATION: DEALS, JANUARY 2022-JUNE 2025
• TABLE 543 SYSMEX CORPORATION: EXPANSIONS, JANUARY 2022-JUNE 2025
• TABLE 544 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
• TABLE 545 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
• TABLE 546 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 547 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022-JUNE 2025
• TABLE 548 AGILENT TECHNOLOGIES, INC.: OTHER DEVELOPMENTS, JANUARY 2022-JUNE 2025
• TABLE 549 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW
• TABLE 550 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCTS OFFERED
• TABLE 551 MERCK KGAA: COMPANY OVERVIEW
• TABLE 552 MERIDIAN BIOSCIENCE: COMPANY OVERVIEW
• TABLE 553 BIO-TECHNE: COMPANY OVERVIEW
• TABLE 554 CELLABS: COMPANY OVERVIEW
• TABLE 555 ABNOVA CORPORATION: COMPANY OVERVIEW
• TABLE 556 J. MITRA & CO. PVT. LTD.: COMPANY OVERVIEW
• TABLE 557 TOSOH CORPORATION (TOSOH BIOSCIENCES): COMPANY OVERVIEW
• TABLE 558 CELL SCIENCES: COMPANY OVERVIEW
• TABLE 559 ENZO BIOCHEM INC.: COMPANY OVERVIEW
• TABLE 560 CREATIVE DIAGNOSTICS: COMPANY OVERVIEW
• TABLE 561 BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW
• TABLE 562 ELABSCIENCE BIONOVATON INC.: COMPANY OVERVIEW
• TABLE 563 WAK-CHEMIE MEDICAL GMBH: COMPANY OVERVIEW
• TABLE 564 SERA CARE: COMPANY OVERVIEW
• TABLE 565 EPITOPE DIAGNOSTICS, INC.: COMPANY OVERVIEW
• TABLE 566 KAMIYA BIOMEDICAL COMPANY: COMPANY OVERVIEW
• TABLE 567 GYROS PROTEIN TECHNOLOGIES AB: COMPANY OVERVIEW
• TABLE 568 TRIVITRON HEALTHCARE: COMPANY OVERVIEW
• TABLE 569 INBIOS INTERNATIONAL, INC.: COMPANY OVERVIEW
• TABLE 570 MACCURA BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW

List of Figures

• FIGURE 1 IMMUNOASSAY MARKET SEGMENTATION & REGIONAL SCOPE
• FIGURE 2 IMMUNOASSAY MARKET: YEARS CONSIDERED
• FIGURE 3 IMMUNOASSAY MARKET: RESEARCH DESIGN
• FIGURE 4 IMMUNOASSAY MARKET: KEY DATA FROM SECONDARY SOURCES
• FIGURE 5 IMMUNOASSAY MARKET: KEY PRIMARY SOURCES
• FIGURE 6 IMMUNOASSAY MARKET: KEY INSIGHTS FROM INDUSTRY EXPERTS
• FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
• FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
• FIGURE 9 IMMUNOASSAY MARKET: COMPANY REVENUE ESTIMATION (REVENUE SHARE ANALYSIS)
• FIGURE 10 IMMUNOASSAY MARKET: CAGR PROJECTIONS (SUPPLY-SIDE ANALYSIS)
• FIGURE 11 IMMUNOASSAY MARKET: TOP-DOWN APPROACH
• FIGURE 12 IMMUNOASSAY MARKET: DATA TRIANGULATION METHODOLOGY
• FIGURE 13 IMMUNOASSAY MARKET, BY PRODUCT, 2025 VS. 2030 (USD BILLION)
• FIGURE 14 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD BILLION)
• FIGURE 15 IMMUNOASSAY MARKET, BY SPECIMEN, 2025 VS. 2030 (USD BILLION)
• FIGURE 16 IMMUNOASSAY MARKET, BY APPLICATION, 2025 VS. 2030 (USD BILLION)
• FIGURE 17 IMMUNOASSAY MARKET, BY END USER, 2025 VS. 2030 (USD BILLION)
• FIGURE 18 REGIONAL SNAPSHOT OF IMMUNOASSAY MARKET
• FIGURE 19 FAVORABLE REGULATORY SCENARIO AND HIGH PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
• FIGURE 20 US AND REAGENTS & KITS COMMANDED LARGEST SHARE OF NORTH AMERICAN IMMUNOASSAY MARKET IN 2024
• FIGURE 21 CHINA TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD
• FIGURE 22 ASIA PACIFIC TO WITNESS HIGHEST CAGR DURING STUDY PERIOD
• FIGURE 23 IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 24 RATE OF INCREASE IN INCIDENCE OF DIABETES GLOBALLY (IN MILLION)
• FIGURE 25 US: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES
• FIGURE 26 CANADA: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES
• FIGURE 27 JAPAN: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES
• FIGURE 28 INDIA: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES
• FIGURE 29 MEXICO: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES
• FIGURE 30 BRAZIL: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES
• FIGURE 31 TOP 10 PATENT OWNERS/APPLICANTS IN IMMUNOASSAY MARKET, JANUARY 2015-DECEMBER 2024
• FIGURE 32 IMMUNOASSAY MARKET: VALUE CHAIN ANALYSIS
• FIGURE 33 IMMUNOASSAY MARKET: SUPPLY CHAIN ANALYSIS
• FIGURE 34 IMMUNOASSAY MARKET: ECOSYSTEM ANALYSIS
• FIGURE 35 IMMUNOASSAY MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 36 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY END USER
• FIGURE 37 KEY BUYING CRITERIA FOR TOP END USERS
• FIGURE 38 IMMUNOASSAY MARKET: TRENDS/DISTRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• FIGURE 39 IMMUNOASSAY MARKET: FUNDING AND NUMBER OF DEALS, 2018-2025 (USD MILLION)
• FIGURE 40 MARKET POTENTIAL OF AI/GEN AI IN ENHANCING IMMUNOASSAY DIAGNOSIS AND TREATMENT PLANNING
• FIGURE 41 NORTH AMERICA: IMMUNOASSAY MARKET SNAPSHOT
• FIGURE 42 ASIA PACIFIC: IMMUNOASSAY MARKET SNAPSHOT
• FIGURE 43 REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNOASSAY MARKET (2020-2024)
• FIGURE 44 MARKET SHARE ANALYSIS OF KEY PLAYERS IN IMMUNOASSAY MARKET (2024)
• FIGURE 45 IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
• FIGURE 46 IMMUNOASSAY MARKET: COMPANY FOOTPRINT
• FIGURE 47 IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
• FIGURE 48 EV/EBITDA OF KEY VENDORS, 2025
• FIGURE 49 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2025
• FIGURE 50 IMMUNOASSAY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
• FIGURE 51 ABBOTT: COMPANY SNAPSHOT
• FIGURE 52 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
• FIGURE 53 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT
• FIGURE 54 DANAHER: COMPANY SNAPSHOT
• FIGURE 55 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
• FIGURE 56 REVVITY: COMPANY SNAPSHOT
• FIGURE 57 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT
• FIGURE 58 DIASORIN S.P.A.: COMPANY SNAPSHOT
• FIGURE 59 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
• FIGURE 60 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT
• FIGURE 61 BIOMERIEUX: COMPANY SNAPSHOT
• FIGURE 62 QIAGEN: COMPANY SNAPSHOT
• FIGURE 63 SYSMEX CORPORATION: COMPANY SNAPSHOT
• FIGURE 64 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
• FIGURE 65 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT